Acute promyelocytic leukaemia in the all trans retinoic acid era

Thomas Deloughery, Scott H. Goodnight

    Research output: Contribution to journalArticle

    1 Citation (Scopus)

    Abstract

    Bleeding diathesis is a common complication of acute promyelocyctic leukaemia (APL). Multiple haemostatic defects are found in most patients with APL, which often worsen following cytoreductive chemotherapy. Besides thrombocytopenia, most patients develop disseminated intravascular coagulation, systemic fibrinolysis or both. A major aim in treating haemostatic defects of APL is to prevent death or disability from bleeding until chemotherapy clears the malignant promyelocytes from the blood and bone marrow. The therapeutic options are discussed in this review and practical guidelines for treatment are outlined.

    Original languageEnglish (US)
    Pages (from-to)233-240
    Number of pages8
    JournalMedical Oncology
    Volume13
    Issue number4
    DOIs
    StatePublished - Dec 1996

    Fingerprint

    Acute Promyelocytic Leukemia
    Tretinoin
    Leukemia
    Hemostatics
    Hemorrhage
    Drug Therapy
    Granulocyte Precursor Cells
    Disseminated Intravascular Coagulation
    Disease Susceptibility
    Fibrinolysis
    Thrombocytopenia
    Bone Marrow
    Guidelines
    Therapeutics

    Keywords

    • haemorrhage
    • promyelocytic leukaemia
    • retinoic acid
    • thrombosis

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research
    • Hematology

    Cite this

    Acute promyelocytic leukaemia in the all trans retinoic acid era. / Deloughery, Thomas; Goodnight, Scott H.

    In: Medical Oncology, Vol. 13, No. 4, 12.1996, p. 233-240.

    Research output: Contribution to journalArticle

    Deloughery, Thomas ; Goodnight, Scott H. / Acute promyelocytic leukaemia in the all trans retinoic acid era. In: Medical Oncology. 1996 ; Vol. 13, No. 4. pp. 233-240.
    @article{65c6a4b140a84095b2610a8ad6d8b4a9,
    title = "Acute promyelocytic leukaemia in the all trans retinoic acid era",
    abstract = "Bleeding diathesis is a common complication of acute promyelocyctic leukaemia (APL). Multiple haemostatic defects are found in most patients with APL, which often worsen following cytoreductive chemotherapy. Besides thrombocytopenia, most patients develop disseminated intravascular coagulation, systemic fibrinolysis or both. A major aim in treating haemostatic defects of APL is to prevent death or disability from bleeding until chemotherapy clears the malignant promyelocytes from the blood and bone marrow. The therapeutic options are discussed in this review and practical guidelines for treatment are outlined.",
    keywords = "haemorrhage, promyelocytic leukaemia, retinoic acid, thrombosis",
    author = "Thomas Deloughery and Goodnight, {Scott H.}",
    year = "1996",
    month = "12",
    doi = "10.1007/BF02990936",
    language = "English (US)",
    volume = "13",
    pages = "233--240",
    journal = "Medical Oncology",
    issn = "1357-0560",
    publisher = "Humana Press",
    number = "4",

    }

    TY - JOUR

    T1 - Acute promyelocytic leukaemia in the all trans retinoic acid era

    AU - Deloughery, Thomas

    AU - Goodnight, Scott H.

    PY - 1996/12

    Y1 - 1996/12

    N2 - Bleeding diathesis is a common complication of acute promyelocyctic leukaemia (APL). Multiple haemostatic defects are found in most patients with APL, which often worsen following cytoreductive chemotherapy. Besides thrombocytopenia, most patients develop disseminated intravascular coagulation, systemic fibrinolysis or both. A major aim in treating haemostatic defects of APL is to prevent death or disability from bleeding until chemotherapy clears the malignant promyelocytes from the blood and bone marrow. The therapeutic options are discussed in this review and practical guidelines for treatment are outlined.

    AB - Bleeding diathesis is a common complication of acute promyelocyctic leukaemia (APL). Multiple haemostatic defects are found in most patients with APL, which often worsen following cytoreductive chemotherapy. Besides thrombocytopenia, most patients develop disseminated intravascular coagulation, systemic fibrinolysis or both. A major aim in treating haemostatic defects of APL is to prevent death or disability from bleeding until chemotherapy clears the malignant promyelocytes from the blood and bone marrow. The therapeutic options are discussed in this review and practical guidelines for treatment are outlined.

    KW - haemorrhage

    KW - promyelocytic leukaemia

    KW - retinoic acid

    KW - thrombosis

    UR - http://www.scopus.com/inward/record.url?scp=0030427832&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0030427832&partnerID=8YFLogxK

    U2 - 10.1007/BF02990936

    DO - 10.1007/BF02990936

    M3 - Article

    C2 - 9152974

    AN - SCOPUS:0030427832

    VL - 13

    SP - 233

    EP - 240

    JO - Medical Oncology

    JF - Medical Oncology

    SN - 1357-0560

    IS - 4

    ER -